More than 20% of total rail carloads stem from the coal industry. Because of this reliance on coal shipments, CSX (NYSE: CSX ) and Norfolk Southern (NYSE: NSC ) each saw revenues from coal shipments drop by double digits in the first quarter of 2013 versus the same quarter last year. This also can't be great news for Warren Buffett's Berkshire Hathaway (NYSE: BRK-A ) , as it owns BNSF railroads, which holds a 33% market share in coal shipments by rail, according to 2012 data.
These companies cater to the eastern United States, which has seen its coal industry hurt to a much greater degree than miners out west, such as Peabody Energy and its Powder River Basin thermal coal production. Coal from this region is produced further down the cost curve and is competitive with much lower natural gas prices than the Appalachian output.
Because exports are becoming a much bigger part of the domestic coal landscape, CSX has chosen to focus on providing greater access to a variety of export terminals. Peabody Energy is just one company that has deals in place to get its cheaper coal from the Powder River and Illinois basins to India, China, and the EU. For investors looking to capitalize on a rebound in the U.S. coal market, The Motley Fool has authored a special new premium report detailing exactly why Peabody Energy is perhaps most worthy of your consideration. Don't miss out on this invaluable resource -- simply click here now to claim your copy today.
10 Best Financial Stocks For 2015: Vical Incorporated(VICL)
Vical Incorporated engages in the research and development of biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its products include Allovectin, a Phase III clinical trial product to treat metastatic melanoma; CyMVectin prophylactic vaccine for cytomegalovirus, which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic and prophylactic vaccines for herpes simplex type 2 virus, which is under preclinical trial to prevent and protect against recurring flare-ups, reduce viral shedding ,and transmission. The company, through corporate collaborations, develops TransVax, which is in Phase III clinical trials to protect against CMV infection after stem cell transplants, as well as in Phase II clinical trial to protect against CMV infection after solid organ transplants; Collategene, an angiogenic therapy enc oding hepatocyte growth factor that is in Phase III clinical trials to induce local growth of blood vessels to restore blood flow to limbs affected by critical limb ischemia; Apex-IHN prophylactic vaccine for infectious hematopoietic necrosis virus for the prevention of infection and disease in farm-raised salmon when exposed to infected wild salmon ; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to increase survival time of dogs with oral melanoma. Vical Incorporated, through government collaboration, develops Prophylactic and/or therapeutic HIV vaccine, a Phase IIb clinical trial product to prevent/treat infection, disease, and/or viral shedding; and Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all 4 dengue serotypes. The company was founded in 1987 and is based in San Diego, California.
Advisors' Opinion:- [By Roberto Pedone]
Another stock that's starting to trend within range of triggering a major breakout trade is Vical (VICL), which engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. This stock has been hit hard by the sellers over the last six months, with shares off sharply by 65%.
If you look at the chart for Vical, you'll notice that this stock has been trending sideways and consolidating over the last two months, with shares moving between $1.01 on the downside and $1.35 on the upside. Shares of VICL have started to uptrend over the last few weeks, with shares moving higher from its low of $1.01 to its recent high of $1.35 a share. During that move, shares of VICL have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now taken shares of VICL back above its 50-day moving average of $1.16 share and it's quickly pushing the stock within range of triggering a major breakout trade.
Traders should now look for long-biased trades in VICL if it manages to break out above some near-term overhead resistance at $1.35 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.17 million shares. If that breakout hits soon, then VICL will set up to re-test or possibly take out its next major overhead resistance level at $1.53 a share to its gap-down day high of $1.61 a share. Any high-volume move above those levels will then give VICL a chance to re-fill some of its previous gap-down-day zone from last August that started at $3.70 a share.
Traders can look to buy VICL off any weakness to anticipate that breakout and simply use a stop that sits just below its 50-day moving average at $1.20 a share or near more support at $1.10 a share. One can also buy VICL off strength once it starts to cle
- [By Roberto Pedone]
Vical (VICL) engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. This stock closed up 5.8% to $1.62 in Tuesday's trading session.
Tuesday's Range: $1.53-$1.63
52-Week Range: $1.37-$4.74
Tuesday's Volume: 7.28 million
Three-Month Average Volume: 1.53 millionFrom a technical perspective, VICL bounced higher here right above its recent 52-week low at $1.37 with monster upside volume. This stock recently gapped down big from $3.75 to $1.37 with huge downside volume. That move has now pushed shares of VICL into extremely oversold territory, since its current relative strength index reading is 21.80. Oversold can always get more oversold, but it's also an area where a stock can experience a powerful bounce higher from.
Traders should now look for long-biased trades in VICL as long as it's trending above its 52-week low at $1.37 and then once it sustains a move or close above Tuesday's high of $1.63 with volume that hits near or above 1.53 million shares. If we get that move soon, then VICL will set up to re-fill some of its previous gap down zone that started at $3.75. Some possible upside targets if VICL gets into that gap with volume are $2.25 to $2.50.
Top 5 Railroad Companies To Invest In Right Now: Actavis Inc (ACT)
Actavis, Inc., formerly Watson Pharmaceuticals, Inc., incorporated on February 1, 1985, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.
Actavis Pharma Segment
Actavis Pharma Segment is engaged in the development, manufacturing and sale of generic, branded generic and OTC pharmaceutical products. The Company�� portfolio of generic products includes products it has developed internally and products licensed from and distributed for third parties. The Company sells its generic prescription products primarily under the Watson Laboratories, Watson Pharma and Actavis Pharma labels, and its over-the-counter generic products under private label.
Actavis Specialty Brands Segment
The Company markets a number of branded products to physicians, hospitals, and other markets that it serves. The Company classifies these trademarked products as its brand pharmaceutical products. In April 2012, it launched Gelnique 3% (oxybutynin), a clear, odorless topical gel. Gelnique 3% was obtained through an exclusive licensing agreement with Antares. The Company�� promoted products are Rapaflo, Gelnique, Trelstar, Androderm, Generess Fe and Crinone. The Company�� Actavis Specialty Brands segment also receives other revenues consisting of co-promotion revenue and royaltie! s.
Anda Distribution Segment
The Company Anda Distribution business primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables and over-the-counter medicines to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains and physicians��offices. In addition, it sells to members of buying groups, which are independent pharmacies that join together to enhance their buying power. As of December 31, 2012, the Company distributes products from its facilities in Weston, Florida, Groveport, Ohio, and Olive Branch, Mississippi, as well as a small volume of product from Puerto Rico.
The Company competes with Teva Pharmaceutical Industries, Ltd., Mylan Inc., Sandoz, Inc, McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc.,
Advisors' Opinion:- [By Sean Williams]
Geared as a secondary line of treatment, Intercept has geared OCA to snatch up patients who have an inadequate response to, or are unable to take, ursodiol, the only drug currently approved to treat PBC. Ursodiol was originally developed by Actavis (NYSE: ACT ) (previously Watson Pharmaceuticals) but has since lost its exclusivity, with Lannett (NYSEMKT: LCI ) gaining FDA approval to market generic versions of the drug in 2008. In the true sense of the word, Intercept has little direct competition as long as ursodiol intolerance exists in some patients.
- [By Rich Smith]
On Friday, shares of branded pharmaceutical manufacturer Warner Chilcott (NASDAQ: WCRX ) jumped 20% in response to rumors that the company was in talks to sell itself to larger rival Actavis (NYSE: ACT ) . Warner also reported steady earnings, where a decline had been expected, and reiterated full-year guidance.
- [By Jake L'Ecuyer]
Equities Trading UP
Forest Laboratories (NYSE: FRX) shot up 29.85 percent to $92.70 after Actavis (NYSE: ACT) announced its plans to buy Forest Labs for $25 billion. Analysts at Morgan Stanley upgraded Forest Labs from Equal-Weight to Overweight.
Top 5 Railroad Companies To Invest In Right Now: J.B. Hunt Transport Services Inc.(JBHT)
J.B. Hunt Transport Services, Inc., together with its subsidiaries, operates as a surface transportation, delivery, and logistics company in North America. It operates in four segments: Intermodal (JBI), Dedicated Contract Services (DCS), Full-Load Dry-Van (JBT), and Integrated Capacity Solutions (ICS). The JBI segment provides intermodal freight solutions, including origin and destination pickup and delivery services in the continental United States, Canada, and Mexico. This segment operates 45,666 pieces of company-controlled trailing equipment; and manages a fleet of 2,592 company-owned tractors. The DCS segment involves in the design, development, and execution of supply chain solutions, which support various transportation networks. This segment offers final mile delivery, replenishment, and specialized services supporting private fleet conversion, fleet creation, and transportation system augmentation. As of December 31, 2010, it operated 4,259 company-owned trucks, 357 customer-owned trucks, and 23 independent contractor trucks. The JBT segment provides full-load, dry-van freight services by utilizing tractors operating over roads and highways. It operated 1,697 company-owned tractors. The ICS segment provides non-asset, asset-light, and transportation logistics solutions. It offers flatbed, refrigerated, expedited, and less-than-truckload, as well as various dry-van and intermodal solutions. The company transports a range of freight, including general merchandise, specialty consumer items, appliances, forest and paper products, building materials, soaps and cosmetics, automotive parts, electronics, and chemicals. J.B. Hunt Transport Services, Inc. was founded in 1961 and is headquartered in Lowell, Arkansas.
Advisors' Opinion:- [By Dan Caplinger]
JB Hunt (NASDAQ: JBHT ) will release its quarterly report next Monday, and the trucking and logistics company has performed impressively in recent months as economic activity within the U.S. has picked up. Even though its competitors tend to draw more attention, JB Hunt's stock has climbed to all-time record highs as investors see the long-term importance of transport to the health of the overall economy and believe that JB Hunt earnings will rise in tandem with economic growth.
- [By Chris Hill]
In this installment of Investor Beat, our analysts explain why they're watching J.B. Hunt Transport Services (NASDAQ: JBHT ) and Wells Fargo (NYSE: WFC ) .
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on JB Hunt Transport Services (Nasdaq: JBHT ) , whose recent revenue and earnings are plotted below. - [By Monica Gerson]
Wall Street expects JB Hunt Transport Services (NASDAQ: JBHT) to post its Q3 earnings at $0.78 per share on revenue of $1.45 billion. JB Hunt Transport shares fell 0.31% to $73.77 in after-hours trading.
Top 5 Railroad Companies To Invest In Right Now: PolyOne Corp (POL)
PolyOne Corporation (PolyOne), incorporated on August 31, 2000, is a provider of specialized polymer materials, services and solutions with operations in specialty polymer formulations, color and additive systems, polymer distribution and specialty vinyl resins. The Company is a specialized developer and manufacturer of additives, liquid colorants, and fluoropolymer and silicone colorants. The Company offers approximately 52,000 polymer solutions to approximately 14,000 customers across the globe. The Company has 60 manufacturing sites and nine distribution facilities in North America, Europe, Asia and South America. The Company operates in four segments: Global Specialty Engineered Materials; Global Color, Additives and Inks; Performance Products and Solutions, and PolyOne Distribution. On January 3, 2011, the Company acquired Uniplen Industria de Polimeros Ltda. (Uniplen). In February 2011, the Company sold its 50% interest in SunBelt Chlor Alkali Partnership (SunBelt). On December 21, 2011, the Company acquired ColorMatrix Group, Inc. In December 2012, the Company acquired Glasforms Inc. Effective March 13, 2013, the Company acquired the interest of Spartech Corporation.
Global Specialty Engineered Materials
Global Specialty Engineered Materials is a provider of custom plastic formulations, services and solutions for designers, assemblers and processors of thermoplastic materials across a range of markets and end-use applications. Its product portfolio includes standard and custom formulated high-performance polymer compounds that are manufactured using thermoplastic compounds and elastomers, which are then combined with advanced polymer additive, reinforcement, filler, colorant and/or biomaterial technologies. The segment includes GLS Corporation (GLS). Global Specialty Engineered Materials has plants, sales and service facilities located throughout North America, Europe and Asia and South America.
Global Color, Additives and Inks
Global Color! , Additives and Inks is a provider of specialized color and additive concentrates, as well as inks and latexes. Its additive masterbatches encompass a range of performance enhancing characteristics and are commonly categorized by the function that they perform, such as ultra violet (UV) stabilization, anti-static, chemical blowing, antioxidant and lubricant, and processing enhancement. Its colorant and additives masterbatches are used in a range of plastics, including those used in food and medical packaging, transportation, building products, pipe and wire and cable markets. The Company also provides custom-formulated liquid systems that meet a variety of customer needs and chemistries, including vinyl, natural rubber and latex, polyurethane and silicone. Products include inks and latexes for diversified markets, including recreational and athletic apparel, construction and filtration, outdoor furniture and healthcare. Global Color, Additives and Inks has plants, sales and service facilities located throughout North America, Europe, Asia and North America.
Performance Products and Solutions
Performance Products and Solutions offers an array of products and services for vinyl coating, molding and extrusion processors principally in North America. Its product offerings include vinyl compounds, vinyl resins, and specialty coating materials based on vinyl. These products are sold to manufacturers of plastic parts and consumer-oriented products. The Company also offers a range of services, including materials testing and component analysis, custom compound development, colorant and additive services, design assistance, structural analyses, process simulations and extruder screw design. Vinyl is utilized across a range of applications in building and construction, wire and cable, consumer and recreation markets, transportation, packaging and healthcare. The segment also includes Producer Services, which offers custom compounding services to resin producers and processors that desig! n and dev! elop their own compound and masterbatch recipes.
PolyOne Distribution
The Company�� PolyOne Distribution business distributes approximately 3,500 grades of engineering and commodity grade resins, including PolyOne-produced compounds, to the North American market. These products are sold to approximately 5,700 custom injection molders and extruders who, in turn, convert them into plastic parts that are sold to end-users in a range of industries. Representing approximately 20 major suppliers, the Company offers its customers a product portfolio, just-in-time delivery from multiple stocking locations and local technical support. During the year ended December 31, 2011, the Company extended its distribution operations to Asia.
Advisors' Opinion:- [By Marc Bastow]
Specialized polymer materials manufacturer and distributor PolyOne (POL) raised its quarterly dividend 33% to 8 cents per share, payable on Jan. 9, 2014 to shareholders of record as of Dec. 17.
POL Dividend Yield: 0.97% - [By Travis Hoium]
What: Shares of PolyOne (NYSE: POL ) jumped 10% today after the company reported earnings.
So what: First quarter revenue was up 7.5% to $801.1 million and adjusted earnings per share rose 29% to $0.31. Analysts expected higher revenue of $817.1 million but only $0.26 in earnings per share so the bottom line is what investors are excited about today. �
No comments:
Post a Comment